Article

OBJECTIVE: To assess the benefit of intra-articular injection of Botulinum toxin
A (BoNT-A) for chronic refractory joint pain regardless of joint or pathology.
DATA SOURCES: The search was performed on Ovid MEDLINE(R) In-Process and Other
Non-Indexed Citations, Ovid MEDLINE(R), Ovid EMBASE,
Web of Science, and Scopus
inception through Week 12, 2016. Trial selection: Clinical randomized controlled
trials that evaluated BoNT-A intra-articular injection in patients with
refractory joint pain were included. DATA EXTRACTION: Two independent reviewers
conducted data extraction. RESULTS: A total of 6 out of 284 records were
included. The analysis indicated that a statistically significant decreased pain
score was found in BoNT-A therapy group than control group with WMD=1.10 (95% CI:
0.35 to 1.85; P<0.001; I2=95%); WMD=0.7 (95% CI: 0.09 to 1.32; P=0.02; I2=0%) at
week 4, and 8 after injection, respectively. WOMAC score was also significant
decreased in BoNT-A therapy group than control group with WMD=4.71 (95% CI: 2.76
to 6.67; P<0.001; I2=0%); WMD=3.67 (95% CI: 1.08 to 6.26;
P=0.006; I2=27%) at
week 4 and12 after injection, respectively. There was no difference in adverse
event between BoNT-A therapy group and control group with OR=1.25 (95% CI: 0.88
to 1.78; P=0.47; I2=0%). CONCLUSION: As compared with conventional therapy,
BoNT-A intra-articular injection have beneficial effects with improved pain score
and WOMAC score in adult patients with refractory joint pain.

Langue : ANGLAIS